Quach H - Search Results

1

The importance of frailty assessment in multiple myeloma: a position statement from the Myeloma Scientific Advisory Group to Myeloma Australia.

Sim S, Kalff A, Tuch G, Mollee P, Ho PJ, Harrison S, Gibbs S, Prince HM, Spencer A, Joshua D, Lee C, Ling S, Murphy N, Szabo F, Szer J, Weber N, Ward C, Talaulikar D, Zannettino A, Quach H. Sim S, et al. Among authors: quach h. Intern Med J. 2023 May;53(5):819-824. doi: 10.1111/imj.16049. Epub 2023 May 10. Intern Med J. 2023. PMID: 36880355 Review.

2

Treatment strategies in elderly patients with multiple myeloma: current status.

Quach H, Prince HM, Mileshkin L. Quach H, et al. Drugs Aging. 2007;24(10):829-50. doi: 10.2165/00002512-200724100-00004. Drugs Aging. 2007. PMID: 17896832 Review.

3

In vivo tracking of dendritic cells in patients with multiple myeloma.

Prince HM, Wall DM, Ritchie D, Honemann D, Harrrison S, Quach H, Thompson M, Hicks R, Lau E, Davison J, Loudovaris M, Moloney J, Loveland B, Bartholeyns J, Katsifis A, Mileshkin L. Prince HM, et al. Among authors: quach h. J Immunother. 2008 Feb-Mar;31(2):166-79. doi: 10.1097/CJI.0b013e31815c5153. J Immunother. 2008. PMID: 18481386

4

Predicting durable remissions following thalidomide therapy for relapsed myeloma.

Quach H, Mileshkin L, Seymour JF, Milner A, Ritchie D, Harrison S, Westerman D, Prince HM. Quach H, et al. Leuk Lymphoma. 2009 Feb;50(2):223-9. doi: 10.1080/10428190802663213. Leuk Lymphoma. 2009. PMID: 19194832 Clinical Trial.

5

Safety and efficacy results from an international expanded access programme to bortezomib for patients with relapsed and/or refractory multiple myeloma: a subset analysis of the Australian and New Zealand data of 111 patients.

Quach H, Horvath N, Cannell P, Mikhael JR, Butcher BE, Prince HM. Quach H, et al. Intern Med J. 2009 May;39(5):290-5. doi: 10.1111/j.1445-5994.2008.01738.x. Epub 2008 Jun 28. Intern Med J. 2009. PMID: 19371392

6

Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma.

Quach H, Ritchie D, Stewart AK, Neeson P, Harrison S, Smyth MJ, Prince HM. Quach H, et al. Leukemia. 2010 Jan;24(1):22-32. doi: 10.1038/leu.2009.236. Epub 2009 Nov 12. Leukemia. 2010. PMID: 19907437 Free PMC article. Review.

7

Testing the NKT cell hypothesis in lenalidomide-treated myelodysplastic syndrome patients.

Chan AC, Neeson P, Leeansyah E, Tainton K, Quach H, Prince HM, Godfrey DI, Ritchie D, Berzins SP. Chan AC, et al. Among authors: quach h. Leukemia. 2010 Mar;24(3):592-600. doi: 10.1038/leu.2009.279. Epub 2010 Jan 14. Leukemia. 2010. PMID: 20072154

8

The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy.

Hsu AK, Quach H, Tai T, Prince HM, Harrison SJ, Trapani JA, Smyth MJ, Neeson P, Ritchie DS. Hsu AK, et al. Among authors: quach h. Blood. 2011 Feb 3;117(5):1605-13. doi: 10.1182/blood-2010-04-278432. Epub 2010 Oct 26. Blood. 2011. PMID: 20978269 Free article.

9

Managing multiple myeloma in the elderly: are we making progress?

Quach H, Prince HM, Spencer A. Quach H, et al. Expert Rev Hematol. 2011 Jun;4(3):301-15. doi: 10.1586/ehm.11.18. Expert Rev Hematol. 2011. PMID: 21668395 Review.

10

A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma.

Harrison SJ, Quach H, Link E, Seymour JF, Ritchie DS, Ruell S, Dean J, Januszewicz H, Johnstone R, Neeson P, Dickinson M, Nichols J, Prince HM. Harrison SJ, et al. Among authors: quach h. Blood. 2011 Dec 8;118(24):6274-83. doi: 10.1182/blood-2011-03-339879. Epub 2011 Sep 12. Blood. 2011. PMID: 21911830 Free article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

328 results

Search Page